Effect of hormone therapy, tibolone and raloxifene on circulating vascular endothelial growth factor in Greek postmenopausal women

European Journal of Endocrinology

Volumn 151, Issue 2, 2004, Pages 187-192

  Christodoulakos, G ^a   Lambrinoudaki, I ^a,c   Panoulis, C ^a   Papadias, C ^a   Sarandakou, A ^a   Liakakos, T ^a   Alexandrou, A ^b   Creatsas, G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE; TIBOLONE; TRIACYLGLYCEROL; VASCULOTROPIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DENSITOMETRY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GREECE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME;

ESTROGEN ANTAGONISTS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GREECE; HUMANS; MEDROXYPROGESTERONE; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; PROSPECTIVE STUDIES; RALOXIFENE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4444289763     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1510187     Document Type: Article

References (42)

1. Sumino H, Nakamura T, Ichikawa S, Tsugiyasu K, Sakamaki T, Sato K, Kobayashi I & Nagai R. Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia. Atherosclerosis 2000 148 189-195.
2. Ylikorkala O, Lim P & Caubel P. Effects on serum lipid profiles of continuous combined 17β-estradiol/norethisterone acetate hormone replacement therapy. Clinical Therapeutics 2000 22 622-626.
3. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 2000 85 214-218.
4. Cicinelli E, Matteo G, Ignarro LJ et al. Acute effects of transdermal estradiol administration on serum levels of nitric oxide in postmenopausal women. Fertility and Sterility 1997 67 63-66.
5. The Writing Group for the Women's Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Journal of the American Medical Association 2002 288 321-333.
6. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Journal of the American Medical Association 1998 280 605-613.
7. Epstein SE, Kornowski R, Fuchs S & Dvorak HF. Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation 2001 104 115-119.
8. Geva E & Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertility and Sterility 2000 74 429-438.
9. Agrawal R, Conway GS, Sladkevicius P, Payne NN, Bekir J, Campbell S et al. Serum vascular endothelial growth factor (VEGF) in the normal menstrual cycle: association with changes in ovarian and uterine Doppler blood flow. Clinical Endocrinology 1999 50 101-106.
10. Waltenberger J. Modulation of growth factor action. Implication for the treatment of cardiovascular diseases. Circulation 1997 96 4083-4094.
11. Friedman CI, Danforth DR, Herbosa-Encarnacion C, Arbogast L, Alak BM & Seifer DB. Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction. Fertility and Sterility 1997 68 607-612.
12. Agrawal R, Prelevic G, Conway GS, Payne NN, Ginsburg J & Jacobs HS. Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. Fertility and Sterility 2000 73 56-60.
13. Timar J, Döme B, Fazekas K, Janovics A & Paku S. Angiogenesis-dependent diseases and angiogenesis therapy. Pathology Oncology Research 2001 7 85-94.
14. Kobayashi M, Matsubara J, Matsushita M, Mishikimi N, Sakurai T & Nimura Y. Expression of angiogenesis and angiogenic factors in human aortic vascular disease. Journal of Surgical Research 2002 106 239-245.
15. Zhao Q, Egashira K, Inoue S, Usui M, Kitamoto S, Ni W et al. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 2002 105 1110-1115.
16. Freedman SB & Isner JM. Therapeutic angiogenesis for coronary artery disease. Annals of Internal Medicine 2002 136 54-71.
17. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR & Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nature Medicine 2001 7 425-429.
18. Rifai N, Warnick GC, McNamara JR, Belcher JD, Grinstead GF & Frantz ID, Jr. Measurement of low-density lipoprotein cholesterol in serum: a status report. Clinical Chemistry 1992 38 150-160.
19. Akkad A & Al-Azzawi F. Changes in serum vascular endothelial growth factor following initiation of estrogen replacement after hysterectomy and oophorectomy. Acta Obstetrica et Gynecologica Scandinavica 2001 80 554-558.
20. Zacharieva S, Atanassova I, Kirilov G, Kalinov K, Shigarminova R, Nachev E et al. Effect of transdermal estrogen therapy on some vasoactive humoral factors and 24-h ambulatory blood pressure in normotensive postmenopausal women. Climacteric 2002 5 293-299.
21. Agrawal R, Prelevic G, Conway GS, Payne NN, Ginsburg J & Jacobs HS. Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. Fertility and Sterility 2000 73 56-60.
22. Belgore FM, Lip GYH & Blann AD. Successful therapy reduces levels of vascular endothelial growth factor (VEGF) in patients with hypertension and patients with hypercholesterolemia. Atherosclerosis 2000 151 599.
23. Blann AD, Belgore FM, Constans J, Conri C & Lip GY. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. American Journal of Cardiology 2001 87 1160-1163.
24. Walldius G & Junger I. Apolipoprotein B and apolipoprotein A-1: risk indicators of coronary heart disease and targets for lipid-modifying therapy. Journal of Internal Medicine 2004 255 188-205.
25. Modelska K & Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. Journal of Clinical Endocrinology and Metabolism 2002 87 16-23.
26. von Eckardstein A, Schmiddem K, Hovels A, Gulbahce E, Schuler-Luttmann S, Elbers J, Helmond F, Bennink HJ & Assmann G. Lowering of HDL cholesterol in postmenopausal women is not associated with changes in cholesterol efflux capacity or paraoxonase activity. Atherosclerosis 2001 159 433-439.
27. De Gooyer M, Deckers G, Schoonen W, Verheul H & Kloosterboer H. Receptor profiling and endocrine interactions of tibolone. Steroids 2003 68 21-30.
28. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. Journal of the American Medical Association 1998 279 1445-1451.
29. Christodoulakos G, Panoulis C, Kouskouni E, Chondros C, Dendrinos S & Creatsas G. Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis. Gynecology and Endocrinology 2002 16 9-17.
30. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 2000 85 214-218.
31. Christodoulakos G, Panoulis C, Lambrinoudaki I, Botsis D, Dendrinos S, Economou E et al. The effect of hormone replacement therapy and raloxifene on serum matrix metalloproteinases -2 and -9 in postmenopausal women. Menopause 2004 11 299-305.
32. Dardes RC, Schafer JM, Pearce ST, Osipo C, Chen B & Jordan VC. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Gynecology and Oncology 2002 85 498-506.
33. Bausero P, Ben-Mahdi M, Mazucatelli J, Bloy C & Perrot-Applanat M. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. American Journal of Physiology. Heart and Circulatory Physiology 2000 279 H2033-H2042.
34. Hyder SM, Chiappetta C, Murthy L & Stancel GM. Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780. Cancer Research 1997 57 2547-2549.
35. McNamara DA, Harmey J, Wang JH, Kay E, Walsh TN & Bouchier-Hayes DJ. Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. European Journal of Surgery and Oncology 2001 27 714-718.
36. Navarro FJ, Mirkin S & Archer DF. Effect of raloxifene, 17beta-estradiol, and progesterone on mRNA for vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 in Ishikawa cells. Fertility and Sterility 2003 79 1409-1415.
37. Krasinski K, Spyridopoulos I, Asahara T, van der Zee R, Isner JM & Losordo DW. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997 95 1768-1772.
38. Jesmin S, Sakuma I, Hattori Y & Kitabatake A. In vivo estrogen manipulations on coronary capillary network and angiogenic molecule expression in middle-aged female rats. Arteriosclerosis, Thrombosis and Vascular Biology 2002 22 1591-1597.
39. Zanger D, Yang BK, Ardans J, Waclawiw MA, Csako G, Wahl LM et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. Journal of the American College of Cardiologists 2000 36 1797-1802.
40. Couffinhal T, Kearney M, Witzenbichler B, Chen D, Murohara T & Losordo DW. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. American Journal of Pathology 1997 150 1673-1685.
41. Cotton JM, Mathur A, Hong Y, Brown AS, Martin JF & Erusalimsky JD. Acute rise of circulating vascular endothelial growth factor-A in patients with coronary heart disease following cardiothoracic surgery. European Heart Journal 2002 23 953-959.
42. McFarlane SI, Myniyappa R, Shin JJ, Bahtiyar G & Sowers JR. Osteoporosis and cardiovascular disease: brittle bones and bones arteries, is there a link? Endocrine 2004 23 1-10.